أعرض في EDS

Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial

التفاصيل البيبلوغرافية
العنوان: Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial
المؤلفون: Xiaoying Han, Liangming Zhang, Xia Yang, Weijun Fan, Junye Wang, Jiao Wang, Dengjun Sun, Guangxu Li, Xin Ye, Hui Tian, Yanjun Xu, Xin Xu, Dianzhong Geng, Cunqi Diao, Licheng Zhang, Yuting Dong, Peishun Li, Haipeng Ren, Chuntang Wang, Lijun Sheng, Zhigeng Zou, Qingyu Li, Fan Li, Aimin Zheng, Guoliang Xue, Guohua Yu, Benhua Zhang, Yahong Sun, Xinglu Xu, Guanghui Huang, Zhigang Wei, Yang Ni, Qingliang Feng, Qi Meng, Wenqiao Sun, Tao Li, Hua Fan, Jingwang Bi, Wenhong Li, Lijun Sun, Yuliang Li, Kaixian Zhang, Bin Liu, Shaoshui Chen, Min Meng
المصدر: European radiology. 30(5)
سنة النشر: 2019
مصطلحات موضوعية: Male, Lung Neoplasms, Organoplatinum Compounds, medicine.medical_treatment, Docetaxel, Kaplan-Meier Estimate, Gastroenterology, Deoxycytidine, 030218 nuclear medicine & medical imaging, Carboplatin, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Prospective Studies, Microwaves, Aged, 80 and over, medicine.diagnostic_test, Microwave ablation, Interventional radiology, Vinorelbine, General Medicine, Middle Aged, Combined Modality Therapy, Progression-Free Survival, Treatment Outcome, 030220 oncology & carcinogenesis, Female, Radiology, Adult, medicine.medical_specialty, Paclitaxel, Adenocarcinoma of Lung, Pemetrexed, Disease-Free Survival, 03 medical and health sciences, Internal medicine, medicine, Humans, Radiology, Nuclear Medicine and imaging, Progression-free survival, Lung cancer, Adverse effect, Aged, Chemotherapy, Radiofrequency Ablation, business.industry, medicine.disease, Gemcitabine, Clinical trial, Cisplatin, Neoplasm Recurrence, Local, business
الوصف: This prospective trial was performed to verify whether microwave ablation (MWA) in combination with chemotherapy could provide superior survival benefit compared with chemotherapy alone. From March 1, 2015, to June 20, 2017, treatment-naive patients with pathologically verified advanced or recurrent non-small cell lung cancer (NSCLC) were randomly assigned to MWA plus chemotherapy group or chemotherapy group. The primary endpoint was progression-free survival (PFS), while the secondary endpoints included overall survival (OS), time to local progression (TTLP), and objective response rate (ORR). The complications and adverse events were also reported. A total of 293 patients were randomly assigned into the two groups. One hundred forty-eight patients with 117 stage IV tumors were included in the MWA plus chemotherapy group. One hundred forty-five patients with 113 stage IV tumors were included in the chemotherapy group. The median follow-up period was 13.1 months and 12.4 months, respectively. Median PFS was 10.3 months (95% CI 8.0–13.0) in the MWA plus chemotherapy group and 4.9 months (95% CI 4.2–5.7) in the chemotherapy group (HR = 0.44, 95% CI 0.28–0.53; p
تدمد: 1432-1084
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7559bf60eaebd0cc94c3eb1ece2ff4a9
https://pubmed.ncbi.nlm.nih.gov/32020400
حقوق: CLOSED
رقم الأكسشن: edsair.doi.dedup.....7559bf60eaebd0cc94c3eb1ece2ff4a9
قاعدة البيانات: OpenAIRE
الوصف
تدمد:14321084